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Unusual course of an abdominal aortic aneurysm
in a patient treated with chemotherapy for gastric
cancer
Juergen Zanow, MD, Yvonne Leistner, MD, Stephan Ludewig, MD, Falk Rauchfuss, MD, and
Utz Settmacher, MD, Jena, Germany
Most aortic aneurysms have a degenerative genesis and show a slow expansion over years. Only a few patients with a rapid
progression of mycotic or inflammatory aneurysm during some weeks or months have been reported. We report a patient
with a rapidly growing symptomatic infrarenal aneurysm with a maximal diameter of 53 mm, which developed over a
5-month period from a normal aorta and did not feature typical signs of degenerative, inflammatory, or mycotic
aneurysm. The aneurysm was successfully treated by endovascular repair. A complete shrinking of the aneurysm sac was
demonstrated during a few weeks postoperatively. Because the patient received chemotherapy with docetaxel, cisplatin,
and 5-fluorouracil for metastatic gastric carcinoma 1 year before the aneurysm occurred, we postulate that chemotherapy
induced a rapid expansion of the aorta in this patient. ( J Vasc Surg 2012;55:841-3.)
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TMost aortic aneurysms have a degenerative genesis and
show a slow expansion over years. Only a few patients with
a rapid progression of mycotic or inflammatory aneurysm
during some weeks or months have been reported. We
report a patient with a rapidly growing symptomatic infra-
renal aneurysm with a maximal diameter of 53 mm that
developed from a normal aorta during a 5-month period
and did not feature typical signs of a degenerative, inflam-
matory, or mycotic aneurysm.
CASE REPORT
A 60-year-old man in good physical and mental status was
referred for abdominal and back pain that had lasted for 2 weeks
and was increasing in intensity. At admission, the patient had an
acute pain at a palpable abdominal aortic aneurysm (AAA). He
was a nonsmoker, had no history of cardiovascular disease, and
had not had a fever during the previous months. Laboratory
tests revealed no abnormal findings other than a highly elevated
C-reactive protein (CRP) level (200 mg/L). In particular, the
white blood cell count, procalcitonin, and creatinine values
were normal.
The patient was diagnosed 1 year before the admission with an
adenocarcinoma of the stomach (uT2, intestinal type) with multi-
ple hepatic metastases. The patient was treated by 10 cycles of
chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, ac-
cording to the established regimen for these agents.1 The patient
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ent-related adverse events other than moderate nausea.
A computed tomography (CT) scan 5 months before the
dmission demonstrated a normal aorta with an axial diameter of
7 mm (Fig 1). A staging CT scan 1 week before admission
howed a significant regression of tumor and metastases, but also a
ewly developed AAAwith amaximal axial diameter of 53mm (Fig
). The aneurysm of the noncalcified infrarenal aorta had no
ntraluminal thrombus. This CT scan revealed minimal periaortic
uid collection and moderate swelling of the left iliopsoas muscle,
nd the infrarenal aorta did not feature the typical signs of an
nflammatory or mycotic AAA (thickened and often calcified aortic
all, a mass of periaortic inflammatory tissue with relative sparing
f the posterior wall).
Despite the very short proximal aneurysm neck length of 10
m, the symptomatic AAA was reconstructed by endovascular
ortic repair (EVAR). The postoperative CT scan revealed the
orrect position of the Endurant endograft (Medtronic, Santa
osa, Calif; main body diameter, 28 mm) and a completely ex-
luded AAA (Fig 3). The patient was discharged on postoperative
ay 5 with minimal back pain and a CRP value of 60 mg/L.
As soon as 6 weeks after the procedure, ultrasound imaging
emonstrated a shrunken AAAwith a maximal diameter of 33mm.
t this time, a gastrectomy, left hepatectomy, and segmentectomy
ere performed, with an uneventful postoperative course. The
reoperative CRP value of 13 mg/L was within the nearly normal
eference range. Histologic examination detected vital tumor cells
n the liver metastases.
A CT scan 6 months after EVAR showed a complete
hrinkage of the aneurysm to the diameter of the endograft (Fig
). The combined positron emission tomography scan detected
o increased metabolic activity in the aortic wall or in any other
ocation.
Contrast-enhanced ultrasound imaging 1 year postoperatively
emonstrated the AAA was unchanged and completely shrunk.
he CT scan confirmed complete shrinkage of the AAA and did
ot show a recurrent or metastatic status of the gastric carcinoma.
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surveillance.
DISCUSSION
Such a rapid development of an AAA of a recently
normal aorta with a diameter expansion by 36 mm, or
triplication of the diameter within a maximum of 5
months, is extremely unusual. For a small AAA of 3.0- to
3.4-cm diameter, a yearly expansion rate of 0.11 to 0.33
cm has been reported.2,3 Also, a rapid complete aneu-
rysm sac retraction over the course of only a few weeks is
very uncommon.4,5 Rapid aneurysm expansion was de-
scribed in single case reports for mycotic6,7 or inflamma-
tory AAAs,8 and for a patient who received chemother-
apy with gemcitabine, cisplatinum, and corticosteroids.9
The etiology of the AAA in this patient remains
Fig 1. A computed tomography scan 5 months before admission
shows a normal aorta.unclear. This is partly because no material was available eor a histologic examination. A degenerative AAA can be
xcluded definitively. An inflammatory aneurysm, idio-
athic aortitis with aneurysmal dilatation, or a mycotic
AA appear to be a possibility, due to the markedly
levated preoperative CRP value and discrete signs of
eriaortal inflammation. A possible leukopenic effect of
revious chemotherapy to otherwise normal laboratory
ests of inflammation may be discussed. However, CT
canning did not demonstrate the typical thickened aor-
ic wall of aortitis or inflammatory AAA.10 The unevent-
ul postoperative course, quick decrease of CRP values
fter one dose of antibiotics, the rapid shrinkage of the
AA, and positron emission tomography findings after
VAR argue against an inflammatory or infectious gen-
ig 2. A symptomatic infrarenal abdominal aortic aneurysm with
diameter of 53 mm is seen at the time of admission. The arrows
ark a minimal periaortic fluid collection and swelling of left
liopsoas muscle.sis of AAA.7,10,11
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the AAA might have been induced by the toxic effects of
chemotherapy, even though there is only an anecdotal
report to support this assumption.9 Acute cardiac toxicity
of 5-fluorouracil is a well-known adverse event,12 but
thrombus formation in a normal aorta13,14 and aortic dis-
section15 represent other and very rare cardiovascular ad-
verse events of chemotherapy. The disturbed synthesis of
DNA, collagen, and elastin, release of cytokines, inhibition
of smooth muscle cell proliferation, and induction of met-
alloproteinases are so far predominately hypothetically for-
mulated effects of chemotherapeutics that might induce
AAA development.9,16,17 A higher incidence of aneurysms
in long-term survivors of cancer treated with chemotherapy
is not known. In contrast, neoplasm concomitant with an
AAA is not uncommon, and EVAR may be a promising
Fig 3. A computed tomography scan at the 6-month follow-up
after endovascular repair reveals complete shrinkage of the abdom-
inal aortic aneurysm.approach for these patients.17,18 SONCLUSIONS
Owing to the rarity of such rapid growth of the AAA,
his case report highlights the biologic variability of AAAs.
or the patient reported here, the performed treatment
ppears correct at this time.
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